A new topical antifungal drug: tioconazole.
Following 4 weeks of treatment, 32 of 35 tioconazole treated patients (91.4%) and 29 of 34 miconazole treated patients (85.3%) achieved clinical and mycologic cures. At follow-up four weeks after completion of treatment, 29 of 31 tioconazole treated patients (93.5%) and 25 of 28 miconazole treated patients (89.3%) remained cured. There was no significant difference between clinical, mycologic or clinical plus mycologic response to the two medications. The 96.2% positive culture correlation in this study is attributed to the selection of multiple culture sites.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008825:Miconazole / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011897:Random Allocation
D000935:Antifungal Agents; D007093:Imidazoles; D008825:Miconazole; C020527:tioconazole